chlortetracycline can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


sulconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Delavirdine can cause a decrease in the absorption of cimetidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of famotidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


mycophenolic acid can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


phenindione can cause a decrease in the absorption of Lixisenatide resulting in a reduced serum concentration and potentially a decrease in efficacy.


bifonazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of FERRIC CITRATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Voriconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


fluconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Artemether can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of ROXATIDINE ACETATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Posaconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of dexlansoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of omeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of olanzapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


griseofulvin can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Delavirdine can cause a decrease in the absorption of olanzapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Micafungin can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Voriconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of FERRIC PYROPHOSPHATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


cefuroxime can cause a decrease in the absorption of doxepin resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of omeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of olanzapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of Asenapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


amphotericin b can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of rabeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Tavaborole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


salicylic acid can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


tolnaftate can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


fluconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nystatin can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of MAGNESIUM SULFATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of doxepin resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of Asenapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Butoconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of MAGNESIUM SULFATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


oxiconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


mycophenolic acid can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


CEFPODOXIME can cause a decrease in the absorption of Asenapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


cefuroxime can cause a decrease in the absorption of olanzapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of lansoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of cimetidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


cefuroxime can cause a decrease in the absorption of nizatidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of pantoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


estramustine can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


EFINACONAZOLE can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of rabeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sertaconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


itraconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Delavirdine can cause a decrease in the absorption of epinastine resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


cefuroxime can cause a decrease in the absorption of epinastine resulting in a reduced serum concentration and potentially a decrease in efficacy.


tioconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


ketoconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


5-Fluorocytosine can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


terbinafine can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pazopanib can cause a decrease in the absorption of epinastine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of FERRIC CITRATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


CEFPODOXIME can cause a decrease in the absorption of ROXATIDINE ACETATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of lansoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of pantoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


CICLOPIROX can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


tolnaftate can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


cefuroxime can cause a decrease in the absorption of ROXATIDINE ACETATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of ranitidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of ROXATIDINE ACETATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


clindamycin can cause a decrease in the absorption of KAOLIN resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of ROXATIDINE ACETATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Delavirdine can cause a decrease in the absorption of ROXATIDINE ACETATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of Esomeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


ethambutol can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of cimetidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


dicumarol can cause a decrease in the absorption of Lixisenatide resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


griseofulvin can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of ranitidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Delavirdine can cause a decrease in the absorption of famotidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of dexlansoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


amiodarone can cause a decrease in the absorption of orlistat resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of famotidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


cerulenin can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Delavirdine can cause a decrease in the absorption of doxepin resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pazopanib can cause a decrease in the absorption of olanzapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


warfarin can cause a decrease in the absorption of Lixisenatide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of omeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


miconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


hexetidine can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of rabeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of nizatidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Tavaborole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


NATAMYCIN can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


cefuroxime can cause a decrease in the absorption of Asenapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


cholic acid can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


bifonazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


CEFPODOXIME can cause a decrease in the absorption of olanzapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.


cefuroxime can cause a decrease in the absorption of cimetidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


cefuroxime can cause a decrease in the absorption of ranitidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


mycophenolic acid can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


mycophenolic acid can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


chloroxine can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


haloprogin can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Miltefosine can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Isoconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Delavirdine can cause a decrease in the absorption of Asenapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


enalapril may increase the hyperkalemic activities of Eplerenone.


Olmesartan may increase the hyperkalemic activities of Aliskiren.


cyclosporin A may increase the hyperkalemic activities of Eplerenone.


Spirapril may increase the hyperkalemic activities of trimethoprim.


AZILSARTAN MEDOXOMIL may increase the hyperkalemic activities of Aliskiren.


irbesartan may increase the hyperkalemic activities of Tolvaptan.


AMILORIDE may increase the hyperkalemic activities of Drospirenone.


TASOSARTAN may increase the hyperkalemic activities of Eplerenone.


Drospirenone may increase the hyperkalemic activities of Olsalazine.


Drospirenone may increase the hyperkalemic activities of suprofen.


lisinopril may increase the hyperkalemic activities of Canagliflozin.


Drospirenone may increase the hyperkalemic activities of Eprosartan.


cilazapril may increase the hyperkalemic activities of Canagliflozin.


Drospirenone may increase the hyperkalemic activities of Teriflunomide.


Drospirenone may increase the hyperkalemic activities of azelastine.


Sacubitril may increase the hyperkalemic activities of Canagliflozin.


cilazapril may increase the hyperkalemic activities of trimethoprim.


benazepril may increase the hyperkalemic activities of trimethoprim.


Candesartan cilexetil may increase the hyperkalemic activities of trimethoprim.


quinapril may increase the hyperkalemic activities of Tolvaptan.


Drospirenone may increase the hyperkalemic activities of niflumic acid.


MOEXIPRIL may increase the hyperkalemic activities of Tolvaptan.


valsartan may increase the hyperkalemic activities of Eplerenone.


irbesartan may increase the hyperkalemic activities of Aliskiren.


Drospirenone may increase the hyperkalemic activities of Sacubitril.


Drospirenone may increase the hyperkalemic activities of Loxoprofen.


Drospirenone may increase the hyperkalemic activities of Choline magnesium trisalicylate.


Drospirenone may increase the hyperkalemic activities of valsartan.


Aliskiren may increase the hyperkalemic activities of NICORANDIL.


Drospirenone may increase the hyperkalemic activities of Masoprocol.


Drospirenone may increase the hyperkalemic activities of ramipril.


Drospirenone may increase the hyperkalemic activities of fenoprofen.


Drospirenone may increase the hyperkalemic activities of ADAPALENE.


Telmisartan may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of salicylic acid.


losartan may increase the hyperkalemic activities of Tolvaptan.


Drospirenone may increase the hyperkalemic activities of trandolapril.


Drospirenone may increase the hyperkalemic activities of rescinnamine.


Spirapril may increase the hyperkalemic activities of AMILORIDE.


cyclosporin A may increase the hyperkalemic activities of TASOSARTAN.


irbesartan may increase the hyperkalemic activities of Eplerenone.


Drospirenone may increase the hyperkalemic activities of chloroquine.


Drospirenone may increase the hyperkalemic activities of TASOSARTAN.


Drospirenone may increase the hyperkalemic activities of Spirapril.


AMILORIDE may increase the hyperkalemic activities of Canagliflozin.


Drospirenone may increase the hyperkalemic activities of mycophenolate mofetil.


ramipril may increase the hyperkalemic activities of Aliskiren.


Drospirenone may increase the hyperkalemic activities of cilazapril.


captopril may increase the hyperkalemic activities of Eplerenone.


ramipril may increase the hyperkalemic activities of trimethoprim.


TASOSARTAN may increase the hyperkalemic activities of Aliskiren.


rescinnamine may increase the hyperkalemic activities of triamterene.


captopril may increase the hyperkalemic activities of Tolvaptan.


Drospirenone may increase the hyperkalemic activities of resveratrol.


rescinnamine may increase the hyperkalemic activities of Eplerenone.


quinapril may increase the hyperkalemic activities of Canagliflozin.


cilazapril may increase the hyperkalemic activities of Aliskiren.


lisinopril may increase the hyperkalemic activities of Tolvaptan.


Eprosartan may increase the hyperkalemic activities of Aliskiren.


TASOSARTAN may increase the hyperkalemic activities of Canagliflozin.


Enalaprilat may increase the hyperkalemic activities of triamterene.


Drospirenone may increase the hyperkalemic activities of Nepafenac.


cyclosporin A may increase the hyperkalemic activities of AZILSARTAN MEDOXOMIL.


Enalaprilat may increase the hyperkalemic activities of AMILORIDE.


Drospirenone may increase the hyperkalemic activities of Salsalate.


Drospirenone may increase the hyperkalemic activities of losartan.


Eprosartan may increase the hyperkalemic activities of Eplerenone.


fosinopril may increase the hyperkalemic activities of Aliskiren.


cyclosporin A may increase the hyperkalemic activities of valsartan.


Drospirenone may increase the hyperkalemic activities of tiaprofenic acid.


fosinopril may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of captopril.


quinapril may increase the hyperkalemic activities of Aliskiren.


rescinnamine may increase the hyperkalemic activities of Canagliflozin.


enalapril may increase the hyperkalemic activities of Aliskiren.


rescinnamine may increase the hyperkalemic activities of Tolvaptan.


Sacubitril may increase the hyperkalemic activities of Tolvaptan.


Drospirenone may increase the hyperkalemic activities of tolmetin.


Drospirenone may increase the hyperkalemic activities of ibuprofen.


benazepril may increase the hyperkalemic activities of Tolvaptan.


triamterene may increase the hyperkalemic activities of Sacubitril.


Enalaprilat may increase the hyperkalemic activities of trimethoprim.


valsartan may increase the hyperkalemic activities of Aliskiren.


lisinopril may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of oxyphenbutazone.


Drospirenone may increase the hyperkalemic activities of MOEXIPRIL.


Aliskiren may increase the hyperkalemic activities of Drospirenone.


captopril may increase the hyperkalemic activities of trimethoprim.


Spirapril may increase the hyperkalemic activities of Aliskiren.


Olmesartan may increase the hyperkalemic activities of Eplerenone.


Olmesartan may increase the hyperkalemic activities of Canagliflozin.


enalapril may increase the hyperkalemic activities of Canagliflozin.


cyclosporin A may increase the hyperkalemic activities of Olmesartan.


Sacubitril may increase the hyperkalemic activities of Aliskiren.


AZILSARTAN MEDOXOMIL may increase the hyperkalemic activities of Canagliflozin.


Drospirenone may increase the hyperkalemic activities of Olopatadine.


captopril may increase the hyperkalemic activities of Aliskiren.


Eplerenone may increase the hyperkalemic activities of nitrofurantoin.


triamterene may increase the hyperkalemic activities of TASOSARTAN.


Drospirenone may increase the hyperkalemic activities of PIRFENIDONE.


Eplerenone may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of Icatibant.


Drospirenone may increase the hyperkalemic activities of Pimecrolimus.


Telmisartan may increase the hyperkalemic activities of Eplerenone.


valsartan may increase the hyperkalemic activities of Tolvaptan.


Sacubitril may increase the hyperkalemic activities of Eplerenone.


AZILSARTAN MEDOXOMIL may increase the hyperkalemic activities of Eplerenone.


losartan may increase the hyperkalemic activities of trimethoprim.


AMILORIDE may increase the hyperkalemic activities of Eplerenone.


Telmisartan may increase the hyperkalemic activities of Tolvaptan.


AMILORIDE may increase the hyperkalemic activities of TASOSARTAN.


Spirapril may increase the hyperkalemic activities of Tolvaptan.


spironolactone may increase the hyperkalemic activities of Eplerenone.


spironolactone may increase the hyperkalemic activities of TASOSARTAN.


Drospirenone may increase the hyperkalemic activities of carprofen.


Drospirenone may increase the hyperkalemic activities of Lumiracoxib.


Olmesartan may increase the hyperkalemic activities of trimethoprim.


fosinopril may increase the hyperkalemic activities of Canagliflozin.


Sacubitril may increase the hyperkalemic activities of NICORANDIL.


rescinnamine may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of Apremilast.


Drospirenone may increase the hyperkalemic activities of diflunisal.


rescinnamine may increase the hyperkalemic activities of NICORANDIL.


Drospirenone may increase the hyperkalemic activities of enalapril.


Eprosartan may increase the hyperkalemic activities of Tolvaptan.


Drospirenone may increase the hyperkalemic activities of diclofenac.


Enalaprilat may increase the hyperkalemic activities of Tolvaptan.


Enalaprilat may increase the hyperkalemic activities of Canagliflozin.


ramipril may increase the hyperkalemic activities of Tolvaptan.


PERINDOPRIL may increase the hyperkalemic activities of Eplerenone.


Drospirenone may increase the hyperkalemic activities of oxaprozin.


captopril may increase the hyperkalemic activities of Canagliflozin.


valsartan may increase the hyperkalemic activities of Canagliflozin.


triamterene may increase the hyperkalemic activities of Canagliflozin.


Drospirenone may increase the hyperkalemic activities of Naftifine.


Drospirenone may increase the hyperkalemic activities of meclofenamic acid.


fosinopril may increase the hyperkalemic activities of Eplerenone.


PERINDOPRIL may increase the hyperkalemic activities of Tolvaptan.


Spirapril may increase the hyperkalemic activities of Canagliflozin.


Drospirenone may increase the hyperkalemic activities of indomethacin.


Eplerenone may increase the hyperkalemic activities of Drospirenone.


Drospirenone may increase the hyperkalemic activities of mesalamine.


triamterene may increase the hyperkalemic activities of Eplerenone.


Enalaprilat may increase the hyperkalemic activities of Eplerenone.


Drospirenone may increase the hyperkalemic activities of Enalaprilat.


triamterene may increase the hyperkalemic activities of Tolvaptan.


MOEXIPRIL may increase the hyperkalemic activities of trimethoprim.


PERINDOPRIL may increase the hyperkalemic activities of trimethoprim.


spironolactone may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of BENZYDAMINE.


enalapril may increase the hyperkalemic activities of Tolvaptan.


Enalaprilat may increase the hyperkalemic activities of spironolactone.


rescinnamine may increase the hyperkalemic activities of AMILORIDE.


trandolapril may increase the hyperkalemic activities of Aliskiren.


Olmesartan may increase the hyperkalemic activities of Tolvaptan.


diltiazem may increase the hyperkalemic activities of dantrolene.


trandolapril may increase the hyperkalemic activities of Eplerenone.


Aliskiren may increase the hyperkalemic activities of Canagliflozin.


Drospirenone may increase the hyperkalemic activities of ZILEUTON.


Drospirenone may increase the hyperkalemic activities of etodolac.


spironolactone may increase the hyperkalemic activities of Sacubitril.


AZILSARTAN MEDOXOMIL may increase the hyperkalemic activities of Tolvaptan.


Spirapril may increase the hyperkalemic activities of Eplerenone.


quinapril may increase the hyperkalemic activities of trimethoprim.


benazepril may increase the hyperkalemic activities of Aliskiren.


cyclosporin A may increase the hyperkalemic activities of Sacubitril.


Drospirenone may increase the hyperkalemic activities of lisinopril.


Drospirenone may increase the hyperkalemic activities of SERATRODAST.


cyclosporin A may increase the hyperkalemic activities of Candesartan cilexetil.


Eprosartan may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of floctafenine.


Drospirenone may increase the hyperkalemic activities of celecoxib.


AMILORIDE may increase the hyperkalemic activities of Tolvaptan.


Drospirenone may increase the hyperkalemic activities of epirizole.


lisinopril may increase the hyperkalemic activities of Eplerenone.


Enalaprilat may increase the hyperkalemic activities of Aliskiren.


Telmisartan may increase the hyperkalemic activities of Canagliflozin.


Enalaprilat may increase the hyperkalemic activities of NICORANDIL.


Eprosartan may increase the hyperkalemic activities of Canagliflozin.


PERINDOPRIL may increase the hyperkalemic activities of Canagliflozin.


Candesartan cilexetil may increase the hyperkalemic activities of Canagliflozin.


Eplerenone may increase the hyperkalemic activities of Tolvaptan.


rescinnamine may increase the hyperkalemic activities of spironolactone.


fosinopril may increase the hyperkalemic activities of Tolvaptan.


Spirapril may increase the hyperkalemic activities of NICORANDIL.


Drospirenone may increase the hyperkalemic activities of salicylamide.


benazepril may increase the hyperkalemic activities of Eplerenone.


PERINDOPRIL may increase the hyperkalemic activities of Aliskiren.


VERAPAMIL may increase the hyperkalemic activities of dantrolene.


Eplerenone may increase the hyperkalemic activities of Canagliflozin.


TASOSARTAN may increase the hyperkalemic activities of Tolvaptan.


spironolactone may increase the hyperkalemic activities of Tolvaptan.


MOEXIPRIL may increase the hyperkalemic activities of Canagliflozin.


Drospirenone may increase the hyperkalemic activities of Etoricoxib.


Drospirenone may increase the hyperkalemic activities of nimesulide.


Drospirenone may increase the hyperkalemic activities of ETOFENAMATE.


irbesartan may increase the hyperkalemic activities of trimethoprim.


valsartan may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of antipyrine.


Drospirenone may increase the hyperkalemic activities of alclofenac.


Drospirenone may increase the hyperkalemic activities of quinapril.


Drospirenone may increase the hyperkalemic activities of benazepril.


Drospirenone may increase the hyperkalemic activities of flurbiprofen.


Drospirenone may increase the hyperkalemic activities of AZILSARTAN MEDOXOMIL.


Drospirenone may increase the hyperkalemic activities of leflunomide.


Drospirenone may increase the hyperkalemic activities of fosinopril.


TASOSARTAN may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of CLONIXIN.


enalapril may increase the hyperkalemic activities of trimethoprim.


cyclosporin A may increase the hyperkalemic activities of Eprosartan.


spironolactone may increase the hyperkalemic activities of triamterene.


Drospirenone may increase the hyperkalemic activities of fenbufen.


losartan may increase the hyperkalemic activities of Canagliflozin.


spironolactone may increase the hyperkalemic activities of Canagliflozin.


Drospirenone may increase the hyperkalemic activities of tolfenamic acid.


Spirapril may increase the hyperkalemic activities of triamterene.


Drospirenone may increase the hyperkalemic activities of PERINDOPRIL.


Drospirenone may increase the hyperkalemic activities of Droxicam.


Drospirenone may increase the hyperkalemic activities of sulfasalazine.


Drospirenone may increase the hyperkalemic activities of BALSALAZIDE.


Drospirenone may increase the hyperkalemic activities of Lornoxicam.


Telmisartan may increase the hyperkalemic activities of Aliskiren.


trandolapril may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of zaltoprofen.


spironolactone may increase the hyperkalemic activities of Drospirenone.


Drospirenone may increase the hyperkalemic activities of Aceclofenac.


trandolapril may increase the hyperkalemic activities of Canagliflozin.


spironolactone may increase the hyperkalemic activities of AMILORIDE.


irbesartan may increase the hyperkalemic activities of Canagliflozin.


spironolactone may increase the hyperkalemic activities of nitrofurantoin.


MOEXIPRIL may increase the hyperkalemic activities of Aliskiren.


rescinnamine may increase the hyperkalemic activities of Aliskiren.


trandolapril may increase the hyperkalemic activities of Tolvaptan.


losartan may increase the hyperkalemic activities of Eplerenone.


AMILORIDE may increase the hyperkalemic activities of Sacubitril.


Drospirenone may increase the hyperkalemic activities of ketorolac.


Drospirenone may increase the hyperkalemic activities of Olmesartan.


Drospirenone may increase the hyperkalemic activities of sulindac.


quinapril may increase the hyperkalemic activities of Eplerenone.


Drospirenone may increase the hyperkalemic activities of nabumetone.


cyclosporin A may increase the hyperkalemic activities of Telmisartan.


ramipril may increase the hyperkalemic activities of Canagliflozin.


losartan may increase the hyperkalemic activities of Aliskiren.


Drospirenone may increase the hyperkalemic activities of Propacetamol.


Drospirenone may increase the hyperkalemic activities of tenoxicam.


Drospirenone may increase the hyperkalemic activities of mefenamic acid.


Drospirenone may increase the hyperkalemic activities of aspirin.


lisinopril may increase the hyperkalemic activities of Aliskiren.


Drospirenone may increase the hyperkalemic activities of NAPROXEN.


Drospirenone may increase the hyperkalemic activities of ketoprofen.


Drospirenone may increase the hyperkalemic activities of Telmisartan.


Sacubitril may increase the hyperkalemic activities of trimethoprim.


tacrolimus may increase the hyperkalemic activities of Eplerenone.


ramipril may increase the hyperkalemic activities of Eplerenone.


MOEXIPRIL may increase the hyperkalemic activities of Eplerenone.


cyclosporin A may increase the hyperkalemic activities of irbesartan.


triamterene may increase the hyperkalemic activities of Drospirenone.


Spirapril may increase the hyperkalemic activities of spironolactone.


Drospirenone may increase the hyperkalemic activities of Magnesium salicylate.


benazepril may increase the hyperkalemic activities of Canagliflozin.


TASOSARTAN may increase the hyperkalemic activities of NICORANDIL.


cilazapril may increase the hyperkalemic activities of Eplerenone.


cilazapril may increase the hyperkalemic activities of Tolvaptan.


AZILSARTAN MEDOXOMIL may increase the hyperkalemic activities of trimethoprim.


Drospirenone may increase the hyperkalemic activities of irbesartan.


oxymorphone may increase the analgesic activities of dextroamphetamine.


butorphanol may increase the analgesic activities of MEPHENTERMINE.


Tramadol may increase the analgesic activities of METHAMPHETAMINE.


ALFENTANIL may increase the analgesic activities of Amfepramone.


ALFENTANIL may increase the analgesic activities of hydroxyamphetamine.


meperidine may increase the analgesic activities of Amfepramone.


propoxyphene may increase the analgesic activities of benzphetamine.


Ethylmorphine may increase the analgesic activities of Lisdexamfetamine.


ALFENTANIL may increase the analgesic activities of benzphetamine.


oxycodone may increase the analgesic activities of MEPHENTERMINE.


propoxyphene may increase the analgesic activities of METHAMPHETAMINE.


pentazocine may increase the analgesic activities of hydroxyamphetamine.


butorphanol may increase the analgesic activities of METHAMPHETAMINE.


buprenorphine may increase the analgesic activities of PSEUDOEPHEDRINE.


oxymorphone may increase the analgesic activities of PSEUDOEPHEDRINE.


DIHYDROCODEINE may increase the analgesic activities of Lisdexamfetamine.


Ethylmorphine may increase the analgesic activities of benzphetamine.


DIPHENOXYLATE may increase the analgesic activities of hydroxyamphetamine.


Normethadone may increase the analgesic activities of AMPHETAMINE.


Tramadol may increase the analgesic activities of MEPHENTERMINE.


HEROIN may increase the analgesic activities of hydroxyamphetamine.


Tapentadol may increase the analgesic activities of hydroxyamphetamine.


buprenorphine may increase the analgesic activities of AMPHETAMINE.


Methadyl acetate may increase the analgesic activities of AMPHETAMINE.


Tapentadol may increase the analgesic activities of benzphetamine.


oxycodone may increase the analgesic activities of benzphetamine.


levorphanol may increase the analgesic activities of AMPHETAMINE.


REMIFENTANIL may increase the analgesic activities of Amfepramone.


propoxyphene may increase the analgesic activities of PSEUDOEPHEDRINE.


Tapentadol may increase the analgesic activities of AMPHETAMINE.


codeine may increase the analgesic activities of Lisdexamfetamine.


HYDROCODONE may increase the analgesic activities of PSEUDOEPHEDRINE.


oxymorphone may increase the analgesic activities of MEPHENTERMINE.


methadone may increase the analgesic activities of MEPHENTERMINE.


Normethadone may increase the analgesic activities of METHAMPHETAMINE.


Normethadone may increase the analgesic activities of dextroamphetamine.


ALFENTANIL may increase the analgesic activities of dextroamphetamine.


Ketobemidone may increase the analgesic activities of PSEUDOEPHEDRINE.


propoxyphene may increase the analgesic activities of dextroamphetamine.


levorphanol may increase the analgesic activities of hydroxyamphetamine.


DIPHENOXYLATE may increase the analgesic activities of AMPHETAMINE.


morphine may increase the analgesic activities of hydroxyamphetamine.


oxymorphone may increase the analgesic activities of METHAMPHETAMINE.


HYDROCODONE may increase the analgesic activities of Lisdexamfetamine.


morphine may increase the analgesic activities of Amfepramone.


nalbuphine may increase the analgesic activities of PSEUDOEPHEDRINE.


oxymorphone may increase the analgesic activities of benzphetamine.


codeine may increase the analgesic activities of hydroxyamphetamine.


levorphanol may increase the analgesic activities of METHAMPHETAMINE.


DIPHENOXYLATE may increase the analgesic activities of Amfepramone.


DEZOCINE may increase the analgesic activities of hydroxyamphetamine.


HYDROCODONE may increase the analgesic activities of benzphetamine.


propoxyphene may increase the analgesic activities of hydroxyamphetamine.


Tapentadol may increase the analgesic activities of MEPHENTERMINE.


Tramadol may increase the analgesic activities of PSEUDOEPHEDRINE.


codeine may increase the analgesic activities of dextroamphetamine.


Ketobemidone may increase the analgesic activities of benzphetamine.


oxymorphone may increase the analgesic activities of Lisdexamfetamine.


buprenorphine may increase the analgesic activities of Amfepramone.


oxycodone may increase the analgesic activities of Lisdexamfetamine.


oxymorphone may increase the analgesic activities of Amfepramone.


DIHYDROCODEINE may increase the analgesic activities of MEPHENTERMINE.


hydromorphone may increase the analgesic activities of MEPHENTERMINE.


nalbuphine may increase the analgesic activities of benzphetamine.


Normethadone may increase the analgesic activities of MEPHENTERMINE.


HEROIN may increase the analgesic activities of benzphetamine.


pentazocine may increase the analgesic activities of Amfepramone.


REMIFENTANIL may increase the analgesic activities of hydroxyamphetamine.


morphine may increase the analgesic activities of PSEUDOEPHEDRINE.


propoxyphene may increase the analgesic activities of MEPHENTERMINE.


levorphanol may increase the analgesic activities of MEPHENTERMINE.


DIHYDROCODEINE may increase the analgesic activities of AMPHETAMINE.


hydromorphone may increase the analgesic activities of PSEUDOEPHEDRINE.


levorphanol may increase the analgesic activities of PSEUDOEPHEDRINE.


HEROIN may increase the analgesic activities of Lisdexamfetamine.


butorphanol may increase the analgesic activities of Lisdexamfetamine.


nalbuphine may increase the analgesic activities of dextroamphetamine.


nalbuphine may increase the analgesic activities of METHAMPHETAMINE.


nalbuphine may increase the analgesic activities of MEPHENTERMINE.


propoxyphene may increase the analgesic activities of Amfepramone.


Normethadone may increase the analgesic activities of hydroxyamphetamine.


codeine may increase the analgesic activities of Amfepramone.


REMIFENTANIL may increase the analgesic activities of MEPHENTERMINE.


Ethylmorphine may increase the analgesic activities of hydroxyamphetamine.


levorphanol may increase the analgesic activities of dextroamphetamine.


DEZOCINE may increase the analgesic activities of MEPHENTERMINE.


Tapentadol may increase the analgesic activities of dextroamphetamine.


Tapentadol may increase the analgesic activities of METHAMPHETAMINE.


ALFENTANIL may increase the analgesic activities of MEPHENTERMINE.


pentazocine may increase the analgesic activities of PSEUDOEPHEDRINE.


Methadyl acetate may increase the analgesic activities of benzphetamine.


DEZOCINE may increase the analgesic activities of METHAMPHETAMINE.


propoxyphene may increase the analgesic activities of AMPHETAMINE.


SUFENTANIL may increase the analgesic activities of benzphetamine.


DIPHENOXYLATE may increase the analgesic activities of PSEUDOEPHEDRINE.


Ketobemidone may increase the analgesic activities of AMPHETAMINE.


butorphanol may increase the analgesic activities of dextroamphetamine.


Ethylmorphine may increase the analgesic activities of Amfepramone.


butorphanol may increase the analgesic activities of Amfepramone.


Normethadone may increase the analgesic activities of benzphetamine.


HEROIN may increase the analgesic activities of MEPHENTERMINE.


SUFENTANIL may increase the analgesic activities of PSEUDOEPHEDRINE.


SUFENTANIL may increase the analgesic activities of hydroxyamphetamine.


nalbuphine may increase the analgesic activities of AMPHETAMINE.


Tramadol may increase the analgesic activities of dextroamphetamine.


SUFENTANIL may increase the analgesic activities of Amfepramone.


Ethylmorphine may increase the analgesic activities of AMPHETAMINE.


morphine may increase the analgesic activities of benzphetamine.


pentazocine may increase the analgesic activities of Lisdexamfetamine.


Ketobemidone may increase the analgesic activities of hydroxyamphetamine.


hydromorphone may increase the analgesic activities of hydroxyamphetamine.


Methadyl acetate may increase the analgesic activities of Lisdexamfetamine.


REMIFENTANIL may increase the analgesic activities of benzphetamine.


meperidine may increase the analgesic activities of hydroxyamphetamine.


DIHYDROCODEINE may increase the analgesic activities of dextroamphetamine.


DIHYDROCODEINE may increase the analgesic activities of METHAMPHETAMINE.


DEZOCINE may increase the analgesic activities of Amfepramone.


hydromorphone may increase the analgesic activities of benzphetamine.


buprenorphine may increase the analgesic activities of hydroxyamphetamine.


ALFENTANIL may increase the analgesic activities of PSEUDOEPHEDRINE.


meperidine may increase the analgesic activities of MEPHENTERMINE.


REMIFENTANIL may increase the analgesic activities of AMPHETAMINE.


methadone may increase the analgesic activities of benzphetamine.


Methadyl acetate may increase the analgesic activities of PSEUDOEPHEDRINE.


DIHYDROCODEINE may increase the analgesic activities of PSEUDOEPHEDRINE.


HYDROCODONE may increase the analgesic activities of METHAMPHETAMINE.


levorphanol may increase the analgesic activities of Lisdexamfetamine.


meperidine may increase the analgesic activities of METHAMPHETAMINE.


meperidine may increase the analgesic activities of dextroamphetamine.


HEROIN may increase the analgesic activities of Amfepramone.


Normethadone may increase the analgesic activities of PSEUDOEPHEDRINE.


buprenorphine may increase the analgesic activities of Lisdexamfetamine.


pentazocine may increase the analgesic activities of AMPHETAMINE.


butorphanol may increase the analgesic activities of hydroxyamphetamine.


Ketobemidone may increase the analgesic activities of dextroamphetamine.


Ketobemidone may increase the analgesic activities of METHAMPHETAMINE.


Ketobemidone may increase the analgesic activities of MEPHENTERMINE.


morphine may increase the analgesic activities of MEPHENTERMINE.


hydromorphone may increase the analgesic activities of Lisdexamfetamine.


meperidine may increase the analgesic activities of benzphetamine.


Tapentadol may increase the analgesic activities of Lisdexamfetamine.


DIPHENOXYLATE may increase the analgesic activities of benzphetamine.


DIHYDROCODEINE may increase the analgesic activities of hydroxyamphetamine.


oxymorphone may increase the analgesic activities of hydroxyamphetamine.


codeine may increase the analgesic activities of MEPHENTERMINE.


methadone may increase the analgesic activities of Lisdexamfetamine.


meperidine may increase the analgesic activities of PSEUDOEPHEDRINE.


codeine may increase the analgesic activities of PSEUDOEPHEDRINE.


meperidine may increase the analgesic activities of Lisdexamfetamine.


HEROIN may increase the analgesic activities of PSEUDOEPHEDRINE.


DEZOCINE may increase the analgesic activities of Lisdexamfetamine.


oxycodone may increase the analgesic activities of dextroamphetamine.


oxycodone may increase the analgesic activities of METHAMPHETAMINE.


HYDROCODONE may increase the analgesic activities of AMPHETAMINE.


DIPHENOXYLATE may increase the analgesic activities of Lisdexamfetamine.


codeine may increase the analgesic activities of AMPHETAMINE.


DIHYDROCODEINE may increase the analgesic activities of benzphetamine.


ALFENTANIL may increase the analgesic activities of METHAMPHETAMINE.


SUFENTANIL may increase the analgesic activities of METHAMPHETAMINE.


SUFENTANIL may increase the analgesic activities of dextroamphetamine.


buprenorphine may increase the analgesic activities of benzphetamine.


buprenorphine may increase the analgesic activities of MEPHENTERMINE.


DEZOCINE may increase the analgesic activities of AMPHETAMINE.


HYDROCODONE may increase the analgesic activities of dextroamphetamine.


Tapentadol may increase the analgesic activities of Amfepramone.


Ethylmorphine may increase the analgesic activities of PSEUDOEPHEDRINE.


levorphanol may increase the analgesic activities of benzphetamine.


pentazocine may increase the analgesic activities of METHAMPHETAMINE.


DEZOCINE may increase the analgesic activities of dextroamphetamine.


methadone may increase the analgesic activities of hydroxyamphetamine.


HEROIN may increase the analgesic activities of dextroamphetamine.


HEROIN may increase the analgesic activities of METHAMPHETAMINE.


butorphanol may increase the analgesic activities of PSEUDOEPHEDRINE.


pentazocine may increase the analgesic activities of dextroamphetamine.


oxycodone may increase the analgesic activities of Amfepramone.


pentazocine may increase the analgesic activities of MEPHENTERMINE.


Methadyl acetate may increase the analgesic activities of METHAMPHETAMINE.


nalbuphine may increase the analgesic activities of Lisdexamfetamine.


Ethylmorphine may increase the analgesic activities of METHAMPHETAMINE.


HEROIN may increase the analgesic activities of AMPHETAMINE.


Tramadol may increase the analgesic activities of hydroxyamphetamine.


codeine may increase the analgesic activities of benzphetamine.


Methadyl acetate may increase the analgesic activities of Amfepramone.


nalbuphine may increase the analgesic activities of hydroxyamphetamine.


Tramadol may increase the analgesic activities of Lisdexamfetamine.


DEZOCINE may increase the analgesic activities of PSEUDOEPHEDRINE.


SUFENTANIL may increase the analgesic activities of MEPHENTERMINE.


REMIFENTANIL may increase the analgesic activities of dextroamphetamine.


REMIFENTANIL may increase the analgesic activities of METHAMPHETAMINE.


SUFENTANIL may increase the analgesic activities of Lisdexamfetamine.


Tramadol may increase the analgesic activities of Amfepramone.


ALFENTANIL may increase the analgesic activities of AMPHETAMINE.


Tramadol may increase the analgesic activities of benzphetamine.


DIHYDROCODEINE may increase the analgesic activities of Amfepramone.


Methadyl acetate may increase the analgesic activities of dextroamphetamine.


SUFENTANIL may increase the analgesic activities of AMPHETAMINE.


Normethadone may increase the analgesic activities of Amfepramone.


morphine may increase the analgesic activities of dextroamphetamine.


morphine may increase the analgesic activities of METHAMPHETAMINE.


ALFENTANIL may increase the analgesic activities of Lisdexamfetamine.


hydromorphone may increase the analgesic activities of dextroamphetamine.


hydromorphone may increase the analgesic activities of METHAMPHETAMINE.


DIPHENOXYLATE may increase the analgesic activities of MEPHENTERMINE.


butorphanol may increase the analgesic activities of benzphetamine.


hydromorphone may increase the analgesic activities of Amfepramone.


REMIFENTANIL may increase the analgesic activities of PSEUDOEPHEDRINE.


hydromorphone may increase the analgesic activities of AMPHETAMINE.


codeine may increase the analgesic activities of METHAMPHETAMINE.


butorphanol may increase the analgesic activities of AMPHETAMINE.


Methadyl acetate may increase the analgesic activities of MEPHENTERMINE.


HYDROCODONE may increase the analgesic activities of Amfepramone.


Ethylmorphine may increase the analgesic activities of MEPHENTERMINE.


methadone may increase the analgesic activities of Amfepramone.


levorphanol may increase the analgesic activities of Amfepramone.


DIPHENOXYLATE may increase the analgesic activities of dextroamphetamine.


DIPHENOXYLATE may increase the analgesic activities of METHAMPHETAMINE.


pentazocine may increase the analgesic activities of benzphetamine.


DEZOCINE may increase the analgesic activities of benzphetamine.


oxycodone may increase the analgesic activities of PSEUDOEPHEDRINE.


oxycodone may increase the analgesic activities of hydroxyamphetamine.


Ketobemidone may increase the analgesic activities of Amfepramone.


Normethadone may increase the analgesic activities of Lisdexamfetamine.


Ethylmorphine may increase the analgesic activities of dextroamphetamine.


propoxyphene may increase the analgesic activities of Lisdexamfetamine.


nalbuphine may increase the analgesic activities of Amfepramone.


HYDROCODONE may increase the analgesic activities of MEPHENTERMINE.


buprenorphine may increase the analgesic activities of dextroamphetamine.


buprenorphine may increase the analgesic activities of METHAMPHETAMINE.


Ketobemidone may increase the analgesic activities of Lisdexamfetamine.


REMIFENTANIL may increase the analgesic activities of Lisdexamfetamine.


HYDROCODONE may increase the analgesic activities of hydroxyamphetamine.


morphine may increase the analgesic activities of Lisdexamfetamine.


Tapentadol may increase the analgesic activities of PSEUDOEPHEDRINE.


Methadyl acetate may increase the analgesic activities of hydroxyamphetamine.


The therapeutic efficacy of citric acid can be decreased when used in combination with GESTODENE.


The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lymecycline.


The therapeutic efficacy of gemeprost can be decreased when used in combination with PIRFENIDONE.


The therapeutic efficacy of Prostaglandin E2 can be decreased when used in combination with carprofen.


The therapeutic efficacy of polythiazide can be decreased when used in combination with Olopatadine.


The therapeutic efficacy of QUINETHAZONE can be decreased when used in combination with Olopatadine.


The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with ADAPALENE.


The therapeutic efficacy of betahistine can be decreased when used in combination with mequitazine.


The therapeutic efficacy of carbamazepine can be decreased when used in combination with mefloquine.


The therapeutic efficacy of Pioglitazone can be decreased when used in combination with methyclothiazide.


The therapeutic efficacy of Iobenguane can be decreased when used in combination with benzphetamine.


The therapeutic efficacy of Gliquidone can be decreased when used in combination with CORTISONE ACETATE.


The therapeutic efficacy of glimepiride can be decreased when used in combination with CYPROTERONE ACETATE.


The therapeutic efficacy of xylometazoline can be decreased when used in combination with Glubionate calcium.


The therapeutic efficacy of gemeprost can be decreased when used in combination with Teriflunomide.


The therapeutic efficacy of GLYCEROL PHENYLBUTYRATE can be decreased when used in combination with diflorasone.


The therapeutic efficacy of indapamide can be decreased when used in combination with ETOFENAMATE.


The therapeutic efficacy of mesalamine can be decreased when used in combination with Magnesium trisilicate.


The therapeutic efficacy of Latanoprostene BUNOD can be decreased when used in combination with sulfasalazine.


The therapeutic efficacy of acarbose can be decreased when used in combination with Levonorgestrel.


The therapeutic efficacy of acarbose can be decreased when used in combination with Drospirenone.


The therapeutic efficacy of trichlormethiazide can be decreased when used in combination with leflunomide.


The therapeutic efficacy of gemeprost can be decreased when used in combination with Masoprocol.


The therapeutic efficacy of Saxagliptin can be decreased when used in combination with hydroflumethiazide.


The therapeutic efficacy of Pregabalin can be decreased when used in combination with CALCIUM GLUCONATE.


The therapeutic efficacy of dienestrol can be decreased when used in combination with phenytoin.


The therapeutic efficacy of indapamide can be decreased when used in combination with oxyphenbutazone.


The therapeutic efficacy of digoxin can be decreased when used in combination with AMILORIDE.


The therapeutic efficacy of glipizide can be decreased when used in combination with polythiazide.


The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with methicillin.


The therapeutic efficacy of chlorpropamide can be decreased when used in combination with piperazine.


The therapeutic efficacy of amcinonide can be decreased when used in combination with mifepristone.


The therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.


The therapeutic efficacy of Alogliptin can be decreased when used in combination with betamethasone.


The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etoricoxib.


The therapeutic efficacy of Linagliptin can be decreased when used in combination with BREXPIPRAZOLE.


The therapeutic efficacy of Aclidinium can be decreased when used in combination with decamethonium.


The therapeutic efficacy of glimepiride can be decreased when used in combination with DESOGESTREL.


The therapeutic efficacy of betahistine can be decreased when used in combination with triprolidine.


The therapeutic efficacy of voglibose can be decreased when used in combination with Drospirenone.